Digital & Innovation
Viatris unveils success factors behind award-winning patient support program: PRIME Awards 2022

In recognising and celebrating excellence in healthcare marketing and communications in the pharmaceutical and life science industry, Health Industry Hub was the proud media partner for the PRIME Awards again this year.
Julie Fish, Digital & Customer Experience (Cx) Lead, Viatris joined Health Industry Hub to reveal the success facts behind the award-winning campaign for Excellence in Patient or Customer Support.
Patient uptake and engagement within patient support programs have historically been low as many companies rely unsuccessfully on clinicians to make the patients aware. Julie reflected on how the team exceled at this challenge to drive uptake and engagement of this successful patient support program.
She discussed how companies like Viatris have a critical role to play in reducing the inequities of care by delivering patient support programs to those living in remote and rural areas, CALD communities and First Nations communities.
In considering future trends, Julie commented on how we can better leverage new digital technologies to design and deliver patient programs in more impactful and cost-effective ways.
News & Trends - MedTech & Diagnostics

Policy paralysis: Private hospitals left to clean up the government’s mess on medical device reforms
Hospitals shouldn’t be forced to grovel to private health insurers to secure funding for essential, lifesaving medical devices. But thanks […]
MoreNews & Trends - Pharmaceuticals

Oncologists pioneer liquid biopsy-guided treatment in lung cancer
Lung cancer is Australia’s leading cause of cancer deaths. Local experts are set to lead a new frontier in personalised […]
MoreMedical and Science

The high cost of record low research funding
Australia has delivered some of the world’s most transformative health and medical breakthroughs – the cochlear implant, the HPV vaccine, […]
MoreNews & Trends - Pharmaceuticals

UCB secures dermatology indication with first dual IL-17A/F inhibitor
UCB’s IL-17A and IL-17F inhibitor has been added to the Australian Register of Therapeutic Goods (ARTG) for adults with moderate […]
More